- Policy
- Korea takes further actions for now-pandemic COVID-19
- by Kim, Jung-Ju Mar 16, 2020 06:28am
- As the outbreak of 2019 novel coronavirus (COVID-19) is spreading worldwide, the Korean government has decided to reinforce prevention of transmission from external source and to take related steps. Besides, the government plans to promptly update ‘Mask App,’ a Smartphone app used for government-issued mask sold at pharmacies. Led by
- Policy
- COVID-19 impacts MOHW pharmaceutical divisions’ personnel
- by Kim, Jung-Ju Mar 16, 2020 06:27am
- Korea’s Ministry of Health and Welfare (MOHW) fighting against COVID-19 outbreak at the forefront, is suffering from manpower vacuum as their directors and senior deputy directors in pharmaceutical affairs have been temporarily transferred. The Pharmaceutical Benefits Division, in charge of pharmaceutical benefit listing, reimbursement stan
- Policy
- Probe that detects COVID-19 was successfully made
- by Kim, Jung-Ju Mar 12, 2020 06:07am
- While global attention is focused on the development of 'COVID-19' therapeutics, government-level development research is also in full swing. The government has succeeded in producing specific proteins to detect these infectious antibodies. The National Institute of Health (President Jun-Wook Kwon) in the KCDC (Director Eun-Kyung Jung) ann
- Policy
- Study for effects of Truvada and Kaletra will continue
- by Lee, Jeong-Hwan Mar 12, 2020 06:06am
- The government plans to continue research on the effectiveness of COVID-19 therapeutic substances and patient administration through various methods such as clinical trials. Following the clinical approval of Remdesivir, It will continue to study the necessity of administering drugs that are expected to be effective in treating corona, su
- Policy
- Court suspends execution of Forsteo price reduction
- by Kim, Jung-Ju Mar 12, 2020 06:03am
- Price reduction of Lilly Korea’s osteoporosis treatment Forsteo (teriparatide) is temporarily deferred, although it was notified earlier to be executed this month. The company has reportedly filed a lawsuit to cancel the government-authorized price reduction. On Feb. 28, Seoul Administrative Court has granted suspension of execution
- Policy
- Ibrance & Besivo were added to the price-volume agreement
- by Lee, Hye-Kyung Mar 10, 2020 01:43pm
- Ildong’s Besivo (Besifovir dipivoxil maleate) & Pfizer Korea’s Ibrance (Palbociclib)75mg/100mg/125mg were added to the price-volume agreement negotiation monitoring of the first quarter of this year. Novartis Korea's Entresto (Sacubitril/Valsartan Sod Hydrate) 50mg/100mg/200mg & Myung In Pharm's Q pam (Levitiracetam) 500mg are also bein
- Policy
- CSL Behring steps into hemophilia treatment market in Korea
- by Lee, Tak-Sun Mar 10, 2020 06:29am
- CSL Behring, a subsidiary of Australian-based global pharmaceutical company CSL, is to join the hemophilia treatment competition in Korea. The company acquired approval on hemophilia B treatment Idelbion injection on Mar. 5, after receiving a marketing license on Afstyla infection, a hemophilia A treatment developed based on SK Chemicals
- Policy
- Remdesivir, clinical trial at the SNUH
- by Lee, Tak-Sun Mar 10, 2020 06:29am
- Gilead's COVID-19 drug candidate, Remdesivir is conducting a clinical trial at Seoul National University Hospital. The trial is a multinational researcher-led clinical trial led by the National Institutes of Health (NIH) under the auspices of the World Health Organization. The MFDS approved Remdesivir’s multinational phase II clinical tri
- Policy
- ‘Korea Passing’ Xolair returns for second attempt on DREC
- by Lee, Hye-Kyung Mar 10, 2020 06:29am
- Although it abruptly dropped out from pricing negotiation in Korea for a better reimbursement listing in China, Novartis’ asthma treatment Xolair (omalizumab) has crossed the first threshold of reimbursement listing in Korea. Daehwa Pharmaceutical’s Liporaxel would proceed to negotiate pricing with National Health Insurance Service (NH
- Policy
- What is the difference between Remdesivir & VSF
- by Lee, Tak-Sun Mar 9, 2020 07:59am
- There are two investigational drugs approved by the MFDS for COVID-19 patients as of the 5th. The first is the antiviral drug 'Remdesivir' of the US global pharmaceutical company Gilead Science, and the other is the antiviral candidate called 'VSF' of Korean bioventure Immunemd. However, the reasons for authorizing the administration of
